Unlike Ozempic and Wegovy, which are solely glucagon-like peptide-1 (GLP-1) receptor agonists, or Mounjaro and Zepbound, which combine GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, retatrutide works by activating three key hormonal pathways
In the 12 mg dose group, 16% of subjects discontinued due to adverse events (AEs), but the overall incidence of severe adverse events (SAEs) was low, about 6%-8%
Rogliani et al
Results Preliminary data from six participants show improvements in the physical component and related subscores of the SF-36 throughout the 12 months
Increases Energy Expenditure via Glucagon Receptor Activation What sets retatrutide apart is its activation of the glucagon receptor, which is associated with increased energy expenditure and fat utilization
Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979)